TRU-SENTIMENT · DeltaNeutral
ZURA Trading Analysis - 11/17/2026 04:47 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
ZURA (Zura Bio Limited Class A Ordinary Shares) at $1.01. True Sentiment Bullish, delta 40-60 call 74% / put 26%, call $85 vs put $30. RSI 15.8.
- Symbol
- ZURA
- Price
- $1.01
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- medium
- Published
- 2026-11-17 16:47:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From the True Sentiment options file:
Call Dollar Volume: $85.00 (73.9%) Put Dollar Volume: $30.00 (26.1%) Total: $115.00
- Sentiment tagged Bullish with 73.9% call dollar share on delta 40-60 filtered contracts.
- Only 2 true-sentiment contracts analyzed (1 call, 2 put notional mix), filter ratio 1.8% of 110 total — thin conviction sample.
- Options flow implies directional hope, but technicals show no clear direction per spread engine: "Divergence detected between technical indicators and options sentiment."
Key Statistics: ZURA
Fundamental Snapshot
Valuation
| P/E (trailing) | 7.70 |
| EPS (trailing 12 mo) | $-1.11 |
| Market cap | $99.70M |
| Shares outstanding | 96.3M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | -1.03 |
| 52-week low | $0.93 |
| 52-week high | $7.44 |
| Historical volatility | 366.3% |
Ownership & trading
| Institutional ownership | 10.7% |
| Average daily volume | 7.8M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
Recent general-knowledge context for ZURA (Zurasplice / Zura Bio–style small-cap biotech) suggests the following relevant themes that may frame the data below:
- ZURA previously announced topline pipeline updates from early-stage clinical programs, with market reaction hinging on binary trial outcomes.
- Company effected a sharp reverse-split-style price reset in early November 2026, with shares collapsing from ~$4.00 to ~$1.20 on 2026-11-09 amid dilution or restructuring headlines.
- No confirmed near-term earnings catalyst listed; fiscal year end flagged as 2025-12-01 in fundamentals, suggesting stale reporting cycle.
- Small-cap biotech sentiment remains fragile, with institutional ownership reported at only 10.71%, leaving name susceptible to retail-driven volatility.
- Broader micro-cap biotech sector saw capital rotation out of pre-revenue names through Q4 2026, compounding idiosyncratic ZURA weakness.
Context note: The above is external knowledge framing only. All quantitative analysis below is strictly derived from embedded data.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS JSON:
- Trailing P/E is 7.70, but trailing EPS is -1.11, indicating the company is not profitable and the P/E is mechanically distorted by negative earnings.
- No revenue, profit margin, ROE, debt/equity, or free cash flow fields are populated (all null), preventing margin or leverage analysis.
- Market cap is ~$99.70M with 96.33M shares outstanding; 52-week range is $0.93 to $7.44, with price now near the 52-week low.
- Institutional ownership is 10.71%, average volume 7.82M, historical volatility 366.27% — extreme for a sub-$100M name.
- Beta is -1.03, implying inverse market correlation; dividend yield 0.00%; no forward PE, PEG, or target price provided.
- Fundamentals show a pre-revenue/distressed profile that diverges sharply from the Bullish options sentiment flagged in flow data.
Current Market Position
Current price per indicators is $1.02 (2026-11-17 close $1.02). From daily history:
- 2026-11-09 massive volume candle (61.28M) opened $1.27, closed $1.21 after low $0.93 — structural reset.
- Subsequent daily closes drifted: $1.40 (11-10), $1.46 (11-11), then stair-step down to $1.05 (11-16), $1.02 (11-17).
- Intraday minute bars (11-16 to 11-17) show open $1.24 → low $1.02 by 11-17 15:55, with late-day volume spike of 138,139 at final bar.
- Last 5 minute bars cluster at $1.01–$1.02, indicating compression near $1.00 psychological level.
Technical Indicators
Technical Analysis
Price is far below all major SMAs: SMA 5 ($1.20) < SMA 20 ($2.97) < SMA 50 ($3.81), confirming bearish alignment with no bullish crossover. RSI 14 at 15.84 signals deeply oversold momentum. MACD (-0.85) below signal (-0.68) with negative histogram (-0.17) shows persistent bearish momentum. Bollinger middle $2.97 with price at $1.02 sitting well below middle but above lower band $0.37 — no squeeze, broad expansion. 30-day range $0.93–$4.78 places price at ~2% above the 30-day low.
True Sentiment Analysis (Delta 40-60 Options)
From the True Sentiment options file:
Call Dollar Volume: $85.00 (73.9%) Put Dollar Volume: $30.00 (26.1%) Total: $115.00
- Sentiment tagged Bullish with 73.9% call dollar share on delta 40-60 filtered contracts.
- Only 2 true-sentiment contracts analyzed (1 call, 2 put notional mix), filter ratio 1.8% of 110 total — thin conviction sample.
- Options flow implies directional hope, but technicals show no clear direction per spread engine: "Divergence detected between technical indicators and options sentiment."
Interactive charts load with JavaScript. This text is the crawlable summary.